RHYTHM PHARMACEUTICALS, INC. 8-K

What Happened

• Rhythm Pharmaceuticals, Inc. (RYTM) announced its financial results for the quarter ended March 31, 2026 in a press release dated May 5, 2026. The company filed a Current Report on Form 8-K (Item 2.02) to disclose these quarterly results and furnished the full press release as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: May 5, 2026 (Current Report on Form 8-K).
• Reporting period: Quarter ended March 31, 2026 (Q1 2026 quarterly results).
• Disclosure form items: Item 2.02 (Results of Operations and Financial Condition); Exhibit 99.1 contains the press release.
• The 8-K furnishes the press release text but does not amend or restate previously filed financial statements in this filing.

Why It Matters

• This filing signals Rhythm has released its latest quarterly earnings and operational update—important for investors tracking earnings, revenue, cash position, clinical and commercial progress. Retail investors should read the Exhibit 99.1 press release for the detailed numbers (revenue, net loss, cash runway) and management commentary, as those specifics drive near-term valuation and strategy assessments.